Cellect Biotechnology (Israel), a developer of a novel stem cell production technology, announced that it has signed a collaboration agreement with Cell2in (South Korea), a company focused on improving the quality of cells.
Cellect Biotechnology, an Israeli biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.
Cell2in is a leading pioneer in the field of cell therapy, is a center for biopharmaceutical R&D and was co-founded by professors from top-ranked universities in South Korea.
According to the agreement, the companies will conduct scientific evaluations combining Cellect’s technology platform ApoGraft™ with Cell2in’s proprietary identification technology FreSHtracer™ which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state.
Cell2in’s FreSHtracer™ technology and its unique characteristics may improve the functionality and efficacy of Cellect’s ApoGraft™ technology through the selection of desirable stem cells and quantification of the expansion process. Better quantification of quality stem cells is expected to lead to continuous improvements in Cellect’s technology platform. Cellect’s and Cell2in’s technologies may also be integrated to produce a complementary advantage with the aim of producing associated improvements in clinical outcomes.
Specifically, Cellect will test Cell2in’s technologies’ ability to: show better and more efficient quantification, as compared to current industry standards, of mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs) using ApoGraft technology; validate, through quantification, that Fas Ligand (FasL), Cellect’s main active ingredient accelerates MSC expansion relative to processes currently used in research and manufacturing; enable development of cell expansion media for MSCs and HSCs, utilizing synergistic technologies, to provide better outcomes.